Kapoose Creek Bio Partners with McMaster on Two New Drug Discovery and Development Studies

McMaster University has embarked on exciting new research collaborations with the biotechnology firm Kapoose Creek Bio (KC Bio) aimed at developing innovative medicines, particularly for neurological conditions like depression. Supported by Canada's prominent funding programs, Mitacs Accelerate and the SOPHIE initiative, these projects promise to advance McMaster's drug discovery efforts while accelerating the development of novel drug candidates.

Eric Brown, a professor in McMaster's Department of Biochemistry and Biomedical Sciences and CEO of KC Bio, emphasizes the importance of academic-industry partnerships for translating research into tangible outcomes. He believes that these collaborations position them well to potentially bring at least one new drug into clinical use while also paving the way for the discovery of more candidates.

The discovery project backed by Mitacs will involve McMaster researchers employing advanced profiling techniques to explore therapeutic compounds from KC Bio's extensive collection of fungal specimens and extracts located at their field station in British Columbia. The goal is to expand KC Bio's library to over 35,000 molecules with therapeutic properties. Brown highlights the collaborative effort in assembling this unique collection crucial for drug candidate exploration.

Students and trainees from McMaster are central to this research initiative. Julia Deisinger, a postdoctoral fellow in Brown's lab, recounts her experience collecting fungal specimens in a biodiverse rainforest setting, underscoring the project's immersive educational aspect.

Brown is optimistic about the potential results of this research endeavor, building on promising precedents. In 2023, KC Bio successfully identified KCB-100, a fungi-derived compound with significant drug-like attributes. This compound has demonstrated the ability to enhance key brain proteins and cross the blood-brain barrier, presenting possibilities for treating various neurological disorders, including depression and Alzheimer’s disease.

With support from the SOPHIE program, KC Bio and McMaster aim to push KCB-100 towards clinical development. Canadian Minister of Artificial Intelligence and Digital Innovation, Evan Solomon, supports these partnerships, acknowledging their role in propelling drug discovery and contributing to a more resilient life sciences sector.

The collaboration focuses on generating vital behavioral and biomarker data essential for guiding KCB-100 through clinical trials and eventual commercial availability. Brown expresses excitement about this scientific journey, noting the significant challenges researchers have faced in developing similar drugs for over two decades. He indicates strong preliminary data supporting KCB-100's potential for clinical application.

If successful, the project may establish a clear framework for the drug discovery and development process that could facilitate the transition of new candidates from the lab to patients. The collaborations have attracted nearly $400,000 in research funding to McMaster's drug discovery ecosystem, benefiting from the expertise of Brown and Professor Gerry Wright.

Overall, these collaborations exemplify the integration of academic research with industry innovations, fostering advancements in health solutions for Canadians and reinforcing the importance of strategic investment in drug discovery initiatives.